INPP5D and autoimmune disease: Its hematopoietic-restricted expression should limit the impact of SHIP-1 targeted drugs to the immune system making SHIP-1 an attractive drug target for use in inflammatory and autoimmune diseases, hematological malignancies as well as in transplantation settings.